Home » Stocks » VYGR

Voyager Therapeutics, Inc. (VYGR)

Stock Price: $8.46 USD 0.08 (0.95%)
Updated November 27, 1:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 316.96M
Revenue (ttm) 197.27M
Net Income (ttm) 40.09M
Shares Out 37.47M
EPS (ttm) 1.07
PE Ratio 7.91
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $8.46
Previous Close $8.38
Change ($) 0.08
Change (%) 0.95%
Day's Open 8.47
Day's Range 8.40 - 8.78
Day's Volume 262,357
52-Week Range 6.26 - 15.26

More Stats

Market Cap 316.96M
Enterprise Value 116.94M
Earnings Date (est) Mar 17, 2021
Ex-Dividend Date n/a
Shares Outstanding 37.47M
Float 24.34M
EPS (basic) 1.07
EPS (diluted) 1.07
FCF / Share -2.95
Dividend n/a
Dividend Yield n/a
Earnings Yield 12.65%
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.21M
Short Ratio 5.10
Short % of Float 4.97%
Beta 1.78
PE Ratio 7.91
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1.61
PB Ratio 1.90
Revenue 197.27M
Operating Income 37.35M
Net Income 40.09M
Free Cash Flow -109.98M
Net Cash 200.02M
Net Cash / Share 5.34
Gross Margin -7.78%
Operating Margin 18.93%
Profit Margin 20.30%
FCF Margin -55.75%
ROA 7.23%
ROE 29.22%
ROIC 36.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (13)

Buy 6
Overweight 2
Hold 5
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$15.33*
(81.21% upside)
Low
10.0
Current: $8.46
High
21.0
Target: 15.33
*Average 12-month price target from 12 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue1047.6210.1414.2217.33-
Revenue Growth1270.14%-24.82%-28.73%-17.96%--
Gross Profit1047.6210.1414.2217.33-
Operating Income-51.68-91.10-71.86-41.30-20.25-14.37
Net Income-43.60-88.29-70.70-40.19-29.67-16.32
Shares Outstanding35.9032.0726.8025.304.190.64
Earnings Per Share-1.21-2.75-2.64-1.59-9.14-27.83
Operating Cash Flow48.67-15.89-61.35-42.4841.30-11.92
Capital Expenditures-7.55-4.31-3.99-5.03-1.03-2.99
Free Cash Flow41.12-20.19-65.34-47.5140.27-14.91
Cash & Equivalents2821561691741947.04
Net Cash / Debt2821561691741947.04
Assets35517718419022911.50
Liabilities25513150.4353.6460.3810.35
Book Value99.5146.45134136169-20.83
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Voyager Therapeutics, Inc.
Country United States
Employees 185
CEO G. Andre Turenne

Stock Information

Ticker Symbol VYGR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VYGR
IPO Date November 11, 2015

Description

Voyager Therapeutics, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and alpha-synuclein program for synucleinopathies, Parkinson's disease, Lewy Body Dementia, and multiple system atrophy. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.